RPG Life Sciences Limited has submitted a formal response to BSE Limited regarding an inquiry about increased trading volume in the company's shares. The communication is addressed to The Chief Manager- Surveillance at BSE Limited's Mumbai office.
The company references BSE's email dated June 12, 2026, with reference number L/SURV/ONL/PV/SG/2026-2027/133, which sought clarification on the volume increase.
In its response, RPG Life Sciences confirms that all information required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been duly disclosed by the Company from time to time. The company specifically states that there is no unpublished event, information, or announcement relating to the operation or performance of the Company that is required to be disclosed to the Stock Exchange(s) under Regulation 30 that may have a bearing on the price/volume of the shares of the Company.
The company attributes the recent increase in trading volume to market conditions and confirms it is not aware of any specific reason for the movement. The response concludes by stating that the matter has been adequately clarified.
The document is digitally signed by Rajesh Ramesh Shirambekar, Head – Legal & Company Secretary, on June 12, 2026 at 14:48:13 IST.
Financial Impact
No financial impact disclosed. The company states there are no undisclosed material events affecting operations or performance.